Lifeward — Third Quarter 2026 Earnings Summary

Lifeward reported third-quarter 2026 revenue of $5.4 million, a 12% decrease from the prior year, driven by an 18% year-over-year increase in AlterG revenue to $3.6 million offset by lower ReWalk sales during its transition to a channel-partner distribution model. The company posted a net loss of $5.1 million, or $1.32 per share, compared to a net loss of $3.2 million in the same period last year, with gross margin declining to 27.4% due to foreign exchange fluctuations and acquisition-related expenses. Lifeward is advancing its strategic shift for ReWalk to expand patient access through established distributors while maintaining coverage under Medicare and major insurance plans. Additionally, the company strengthened its clinical evidence base with two new peer-reviewed studies and continues to develop AI-enabled rehabilitation technologies alongside its Protein Oral Delivery platform.